Aura Biosciences (NASDAQ:AURA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10), Zacks reports.
Aura Biosciences Trading Down 3.4%
Shares of Aura Biosciences stock traded down $0.28 during mid-day trading on Tuesday, reaching $7.91. 152,571 shares of the stock were exchanged, compared to its average volume of 347,556. The company has a market cap of $507.82 million, a price-to-earnings ratio of -4.43 and a beta of 0.37. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $9.53. The firm has a 50-day simple moving average of $6.76 and a 200 day simple moving average of $6.08.
Analysts Set New Price Targets
A number of analysts have weighed in on AURA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a report on Friday, March 27th. Wall Street Zen raised shares of Aura Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, HC Wainwright raised their price objective on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $21.50.
Insider Transactions at Aura Biosciences
In other Aura Biosciences news, insider Conor Kilroy sold 11,738 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $7.02, for a total value of $82,400.76. Following the completion of the sale, the insider owned 217,835 shares in the company, valued at approximately $1,529,201.70. This trade represents a 5.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $5.64, for a total transaction of $39,044,986.80. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 7,039,175 shares of company stock worth $39,656,217. Corporate insiders own 6.30% of the company’s stock.
Institutional Investors Weigh In On Aura Biosciences
Several institutional investors have recently modified their holdings of AURA. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aura Biosciences during the 1st quarter worth approximately $137,000. Invesco Ltd. acquired a new stake in shares of Aura Biosciences during the 2nd quarter worth approximately $76,000. Nantahala Capital Management LLC grew its position in shares of Aura Biosciences by 67.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock worth $13,257,000 after buying an additional 850,000 shares during the period. Ameriprise Financial Inc. grew its position in shares of Aura Biosciences by 31.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company’s stock worth $529,000 after buying an additional 20,065 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in Aura Biosciences during the 2nd quarter worth approximately $102,000. Institutional investors and hedge funds own 96.75% of the company’s stock.
About Aura Biosciences
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Read More
- Five stocks we like better than Aura Biosciences
- Shake Shack Stock Gets Shaken After Earnings Miss
- On Holdings Sets Up for Marathon Rally: New Highs Are Coming
- The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000
- MP Materials Is Quietly Building a Rare Earth Powerhouse
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
